Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kamila Kaminska"'
Autor:
Martin Lauss, Bengt Phung, Troels Holz Borch, Katja Harbst, Kamila Kaminska, Anna Ebbesson, Ingrid Hedenfalk, Joan Yuan, Kari Nielsen, Christian Ingvar, Ana Carneiro, Karolin Isaksson, Kristian Pietras, Inge Marie Svane, Marco Donia, Göran Jönsson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Immune checkpoint blockade (ICB) has improved outcome for patients with metastatic melanoma but not all benefit from treatment. Several immune- and tumor intrinsic features are associated with clinical response at baseline. However, we need
Externí odkaz:
https://doaj.org/article/106ca4c71cf547479bf6c2a98fc56d68
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and
Externí odkaz:
https://doaj.org/article/73e69d21bd364412a70101afb76ad7da
Autor:
Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Abstract Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need
Externí odkaz:
https://doaj.org/article/7cbcb174cf144b08807aab383e525e6b
Autor:
Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/df7e78eab9c643b4bcc917eea8a3ff30
Autor:
Henrik J. Ditzel, Lukas Beumers, Anna Ebbesson, Sidse Ehmsen, Katja Harbst, Alejandro Pérez-Fidalgo, Åke Borg, Kamila Kaminska, Anna Ehinger, Ingrid Hedenfalk, Ana Bosch, Johan Staaf, Gabriella Honeth, Srinivas Veerla, Nina Akrap, Carla Maria Lourenco Alves, Signe Borgquist
Publikováno v:
Kaminska, K, Akrap, N, Staaf, J, Alves, C L, Ehinger, A, Ebbesson, A, Hedenfalk, I, Beumers, L, Veerla, S, Harbst, K, Ehmsen, S, Borgquist, S, Borg, Å, Pérez-Fidalgo, A, Ditzel, H J, Bosch, A & Honeth, G 2021, ' Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer ', Breast Cancer Research, vol. 23, no. 1, 26 . https://doi.org/10.1186/s13058-021-01402-1
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Background Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609cd3b141c557d10545f07257a75a91
https://pure.au.dk/portal/da/publications/distinct-mechanisms-of-resistance-to-fulvestrant-treatment-dictate-level-of-er-independence-and-selective-response-to-cdk-inhibitors-in-metastatic-breast-cancer(76ba9d6a-cca3-4b66-8afa-dbead4115cce).html
https://pure.au.dk/portal/da/publications/distinct-mechanisms-of-resistance-to-fulvestrant-treatment-dictate-level-of-er-independence-and-selective-response-to-cdk-inhibitors-in-metastatic-breast-cancer(76ba9d6a-cca3-4b66-8afa-dbead4115cce).html
Autor:
Ana Bosch, Mikkel G. Terp, Henrik J. Ditzel, Monique F. Hundebøl, Neil Portman, Lene E. Johansen, Kamila Kaminska, Gabriella Honeth, Carla Maria Lourenco Alves, Martin Bak, Odd L. Gammelgaard, Elgene Lim, Martina Tuttolomondo, Sidse Ehmsen
Publikováno v:
Nature Communications
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring t
Autor:
Ana Bosch, Carla Maria Lourenco Alves, Henrik J. Ditzel, Martina Tuttolomondo, Mikkel G. Terp, Elgene Lim, Lene E. Johansen, Monique F. Hundebøl, Kamila Kaminska, Gabriella Honeth, Martin Bak, Odd L. Gammelgaard, Neil Portman, Sidse Ehmsen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Autor:
Kamila Kaminska, Ana Bosch, Signe Borgquist, Åke Borg, Nina Akrap, Johan Staaf, Gabriella Honeth
Publikováno v:
Cancer Research. 77:P3-04
Background Estrogen receptor (ER) is a main driver of tumor progression in ER+ metastatic breast cancer (MBC). The use of endocrine therapy can effectively control the disease in a large proportion of patients. However, the majority of MBC eventually
Publikováno v:
Cancer Research. 78:5907-5907
Endocrine therapy is the mainstay of treatment for metastatic estrogen receptor (ER) positive breast cancer. The selective ER degrader (SERD) fulvestrant is increasingly relevant due to its high therapeutic efficacy and often used in combination with
Publikováno v:
Power and Education. 2:341-346